Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.21M Sell
9,417
-123
-1% -$14.4K 0.34% 64
2026
Q1
$1.15M Buy
9,540
+1,313
+16% +$152K 0.4% 54
2025
Q4
$866K Sell
8,227
-1,697
-17% -$159K 0.32% 65
2025
Q3
$833K Sell
9,924
-315
-3% -$25.9K 0.33% 63
2025
Q2
$811K Sell
10,239
-823
-7% -$65.4K 0.37% 55
2025
Q1
$993K Sell
11,062
-2,542
-19% -$237K 0.53% 39
2024
Q4
$1.35M Sell
13,604
-444
-3% -$45.8K 0.68% 29
2024
Q3
$1.6M Sell
14,048
-1,499
-10% -$178K 0.83% 24
2024
Q2
$1.92M Buy
15,547
+1,537
+11% +$198K 0.96% 16
2024
Q1
$1.85M Sell
14,010
-5,721
-29% -$705K 1.12% 12
2023
Q4
$2.15M Buy
+19,731
New +$2.05M 1% 9

Other funds holding MRK

Everpar Advisors's MRK Position: Q2 2026 in Review

Everpar Advisors reduced its Merck (MRK) stake by 1.3% in Q2 2026, selling an estimated $14.4K and leaving 9,417 shares worth $1.21M. The position accounts for 0.34% of the portfolio, ranked #64.

Everpar Advisors first reported a position in MRK in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.15M in Q4 2023. 711 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Everpar Advisors held 9,417 shares of Merck worth $1.21M as of Q2 2026.
  • Everpar Advisors sold 123 Merck shares in Q2 2026, an estimated $14.4K.
  • Merck made up 0.34% of Everpar Advisors's portfolio in Q2 2026, its #64 holding.
  • Everpar Advisors first reported a position in Merck in Q4 2023 and has held it in 11 quarters since.
  • Everpar Advisors's Merck position peaked at $2.15M in Q4 2023.
  • 711 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Everpar Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.